{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-26-004679","form_type":"8-K","ticker":"VOGX","cik":"0001903784","company_name":"Vogenx, Inc.","filed_at":"2026-10-09T17:30:37+00:00","discovered_at":"2026-10-09T17:32:00.268128+00:00","generated_at":"2026-10-12T15:13:49.067059+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vogenx taps board member Richard Gorman as Chief Commercial Officer, effective Oct 12","bullets":["Richard Gorman, an independent Vogenx director since 2022, becomes Chief Commercial Officer effective October 12, 2026, a newly created role.","Gorman resigned from the Board and its Audit, Compensation and Nominating/Corporate Governance committees effective Oct 12; no disagreement with the company cited.","He will lead commercial operations and corporate strategy, including market development for post-bariatric hypoglycemia and gastroparesis, plus business development and licensing.","Vogenx will search for a new independent director to fill the board seat; CEO James Green credited Gorman with shaping strategy through the August 2026 IPO.","Company says the hire supports advancing mizagliflozin into later-stage development; Gorman has 30 years of biopharma commercial experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-004679","json":"https://secwatch.observer/filing/0001185185-26-004679.json","markdown":"https://secwatch.observer/filing/0001185185-26-004679.md","text":"https://secwatch.observer/filing/0001185185-26-004679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1903784/000118518526004679/0001185185-26-004679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1903784/000118518526004679/vogenx8k100826.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:13:49.067059+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"297b367cf1","claim":"Richard Gorman resigned as Director at Vogenx, Inc..","evidence_excerpt":"Richard Gorman resigned from the Board of Directors (“Board”) of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1903784/000118518526004679/0001185185-26-004679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"377065400d","claim":"Richard Gorman was appointed as Chief Commercial Officer at Vogenx, Inc..","evidence_excerpt":"concurrent with his becoming an employee of Vogenx, Inc. (the “Company”) as Chief Commercial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1903784/000118518526004679/0001185185-26-004679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}